SE512781C2 - Oil preparations with high activity antioxidants, and process for their preparation - Google Patents
Oil preparations with high activity antioxidants, and process for their preparationInfo
- Publication number
- SE512781C2 SE512781C2 SE9302141A SE9302141A SE512781C2 SE 512781 C2 SE512781 C2 SE 512781C2 SE 9302141 A SE9302141 A SE 9302141A SE 9302141 A SE9302141 A SE 9302141A SE 512781 C2 SE512781 C2 SE 512781C2
- Authority
- SE
- Sweden
- Prior art keywords
- oil
- preparation
- fine powder
- heated
- sesame
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims description 9
- 230000008569 process Effects 0.000 title claims description 5
- 239000003963 antioxidant agent Substances 0.000 title abstract description 36
- 230000000694 effects Effects 0.000 title abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 34
- 235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 26
- 240000007594 Oryza sativa Species 0.000 claims abstract description 19
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 19
- 235000009566 rice Nutrition 0.000 claims abstract description 19
- 241000209140 Triticum Species 0.000 claims abstract description 17
- 235000021307 Triticum Nutrition 0.000 claims abstract description 17
- 238000010438 heat treatment Methods 0.000 claims abstract description 16
- 244000068988 Glycine max Species 0.000 claims abstract description 12
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 12
- 244000000231 Sesamum indicum Species 0.000 claims abstract 4
- 239000007858 starting material Substances 0.000 claims description 20
- 240000005979 Hordeum vulgare Species 0.000 claims description 9
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 244000077995 Coix lacryma jobi Species 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000012254 powdered material Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 10
- 239000001301 oxygen Substances 0.000 abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 abstract description 10
- -1 lipid peroxide Chemical class 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 235000013339 cereals Nutrition 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 69
- 235000019198 oils Nutrition 0.000 description 69
- 235000006708 antioxidants Nutrition 0.000 description 34
- 241000207961 Sesamum Species 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000008159 sesame oil Substances 0.000 description 7
- 235000011803 sesame oil Nutrition 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 235000006089 Phaseolus angularis Nutrition 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 240000007098 Vigna angularis Species 0.000 description 2
- 235000010711 Vigna angularis Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- KJHJAABRDASKAF-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione Chemical compound OC1=NC(O)=C2N=CNC2=N1.O=C1NC(=O)NC2=C1NC=N2 KJHJAABRDASKAF-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000010716 Vigna mungo Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/10—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material
- B32B3/12—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material characterised by a layer of regularly- arranged cells, e.g. a honeycomb structure
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/50—Soya sauce
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
- B29D24/00—Producing articles with hollow walls
- B29D24/002—Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled
- B29D24/005—Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled the structure having joined ribs, e.g. honeycomb
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/06—Production of fats or fatty oils from raw materials by pressing
- C11B1/08—Production of fats or fatty oils from raw materials by pressing by hot pressing
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Mechanical Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Fats And Perfumes (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
15 20 25 30 35 512781 2 Det botaniska näringsämnet i nr 1 366 268 erhålls ge- nom blandning av färskt tepulver, pulver av värmebehand- lat, opolerat ris och sojabönspulver; tillsättning av en liten mängd koji-svampar till blandningen; därefter ned- sänkning av denna pulverblandning i en blandning av sesam- olja och sojabönsolja under ca 4 dagar för att extrahera effektiva komponenter; borttagning av fällningar genom centrifugering: och inkapsling av återstående oljeämnen i en kapsel gjord av gelatin eller liknande. 15 20 25 30 35 512781 2 The botanical nutrient of heading 1 366 268 is obtained by mixing fresh tea powder, heat-treated powder, unpolished rice and soybean powder; adding a small amount of koji mushrooms to the mixture; then immersing this powder mixture in a mixture of sesame oil and soybean oil for about 4 days to extract effective components; removal of precipitates by centrifugation: and encapsulation of residual oils in a capsule made of gelatin or the like.
Antioxidantkompositionen i nr 63-79834 erhålls genom mild värmning av plantfrön eller groddar därav för att inte bränna vid det; därefter fermentering av dessa värmda växtmaterial genom tillsättning av en mikroorganism; och tillsättning av en växtolja, som erhållits från en växt, som också värmts milt. Eventuellt sätts C-vitamin, C-vita- minderivat eller en växtkropp innehållande dessa till kom- positionen.The antioxidant composition of heading 63-79834 is obtained by gentle heating of plant seeds or seeds thereof so as not to burn upon it; then fermenting these heated plant materials by adding a microorganism; and adding a vegetable oil obtained from a plant which is also mildly heated. Vitamin C, vitamin C derivatives or a plant body containing these may be added to the composition.
Som växtfrön används ett frö, som innehåller antioxi- danter, såsom ovannämnda flavonoider, polyfenoler, garv- syraämnen, tokoferoler, B -vitamin och liknande, inbegri- hato- mugi (pärlkorn) och ärtor. Som växtolja används sesamolja, natt- l pet ris, vete, korn, sojabönor, adzukibönor, majs, sojabönsolja, bomullsfröolja, majsolja, safflorolja, ljusolja, riskliolja, rapsolja, olivolja och liknande. i nr 1 366 268 har emel- lertid låg antioxidantaktivitet på grund av behandlings- Det botaniska näringsämnet förfarandet för det råa växtmaterialet. nr 63-79834 undan- röjde ett sådant problem genom att man anmärksvärt ökade Antioxidantkompositionen i Niwa, aktiviteten hos antioxidanterna genom mild värmning av det råa växtmaterialet med infraröd strålning i det långvàgiga Således förhindrades deaktivering av antioxidanterna beroende på hög tempera- området för att inte bränna vid det. tur. På så sätt frigjordes och omvandlades råmaterialet till effektiva komponenter med låg molekylvikt. Det pà så sätt värmebehandlade materialet fermenterades för att gyn- na vidare frigörning och omvandling till de effektiva ämnena med låg molekylvikt. 10 15 20 25 30 35 512781 3 Enligt studien, som gjorts av föreliggande uppfinnare sedan dess, har man emellertid klargjort att även om de ovannämnda, antioxidanterna markant undertrycker fram- ställningen av det reaktiva syret och lipidperoxiden i teströr, visar sig inte antioxidantaktiviteterna tillräck- ligt i människokroppen.As plant seeds, a seed containing antioxidants is used, such as the above-mentioned flavonoids, polyphenols, tannic acids, tocopherols, B vitamins and the like, including hatomugi (pearl barley) and peas. As vegetable oil, sesame oil, evening primrose rice, wheat, barley, soybeans, adzuki beans, corn, soybean oil, cottonseed oil, corn oil, safflower oil, light oil, rice oil, rapeseed oil, olive oil and the like are used. in No. 1 366 268, however, has low antioxidant activity due to the treatment The botanical nutrient process for the raw plant material. No. 63-79834 eliminated such a problem by remarkably increasing the Antioxidant composition of Niwa, the activity of the antioxidants by gently heating the crude plant material with infrared radiation in the long wave. Thus, deactivation of the antioxidants due to high temperature range was prevented from burning. at that. lucky. In this way, the raw material was released and converted into efficient components with low molecular weight. The heat-treated material thus fermented to promote further release and conversion to the low molecular weight effective substances. However, according to the study conducted by the present inventors since then, it has been clarified that although the above-mentioned antioxidants markedly suppress the production of the reactive oxygen and lipid peroxide in test tubes, the antioxidant activities do not prove to be sufficient. in the human body.
Man anser att det är nödvändigt för antioxidanterna att passera genom cellmembranen, som täcker ytan av cel- lerna, för att medge antioxidanterna att komma in pà in- sidan av celler, som lider av en sjukdom, såsom en inflam- mationsreaktion eller liknande, pà grund av reaktivt syre och lipidperoxid. Människans cellmembran är emellertid rikt pà olje- och fettkomponenter och har sàledes,en sådan egenskap att endast oljeämnen fàr passera igenom. Således har den ovannämnda antioxidantkompositionen med làg halt av oljeämnen en liten möjlighet att passera genom cell- membranet för att penetrera in pà insidan av cellen.It is considered necessary for the antioxidants to pass through the cell membranes, which cover the surface of the cells, to allow the antioxidants to enter the inside of cells suffering from a disease, such as an inflammatory reaction or the like, on due to reactive oxygen and lipid peroxide. However, the human cell membrane is rich in oil and fat components and thus has such a property that only oil substances are allowed to pass through. Thus, the above-mentioned low oil content antioxidant composition has little opportunity to pass through the cell membrane to penetrate the inside of the cell.
Föreliggande uppfinnare har sàledes upprepat studier- na för att förbättra antioxidantkompositionens möjlighet att passera genom cellmembranet, medan man gör ytterligare förbättringar i val av växtarter, som ràmaterial, och dess framställningsförfarande. Som en konsekvens därav, har man erhållit ett oljepreparat i vilket aktiviteten hos anti- oxidanterna, som effektiva komponenter, är hög och genom- trängningsmöjligheten till insidan av cellen, som lider av en sjukdom, är hög, varvid detta utgör föreliggande upp- finning.Thus, the present inventors have repeated the studies to improve the ability of the antioxidant composition to pass through the cell membrane, while making further improvements in the choice of plant species, as a raw material, and its production process. As a consequence, an oil preparation has been obtained in which the activity of the antioxidants, as effective components, is high and the permeability to the inside of the cell, which suffers from a disease, is high, this constituting the present invention.
BESKRIVNING AV FÖRELIGGANDE UPPFINNING Ett ändamàl med föreliggande uppfinning är att man àstadkommer ett oljepreparat och dess framställningsför- farande, i vilket preparat aktiviteten hos antioxidanter, som effektiva komponenter, är hög och genomträngningsmöj- ligheten till insidan av cellen vid ett sjukdomsställe är hög.DESCRIPTION OF THE PRESENT INVENTION An object of the present invention is to provide an oil preparation and its manufacturing process, in which preparation the activity of antioxidants, as effective components, is high and the permeability to the inside of the cell at a disease site is high.
Framställningsförfarande för oljepreparatet enligt föreliggande uppfinning omfattar: värmning av risgroddar och/eller vetegroddar och sojabönor vid en temperatur, som 10 15 20 25 30 35 512781 4 inte överskrider lOO°C; tillförsel av koji till det värmda materialet; fermentering av blandningen; sedan pulvrise- ring av blandningen; och tillförsel av den erhållna, pul- verformade blandningen till en oljeblandning omfattande en som erhållits från sesam, olja, som värmts vid en tempera- tur, som inte överskrider lOO°C, och en olja, som erhål- lits från rå sesam, varvid ett förhållande mellan olje- blandningen och en total mängd av pulverblandningen och oljeblandningen är 60-95 vikt%.The manufacturing process of the oil composition of the present invention comprises: heating rice sprouts and / or wheat sprouts and soybeans at a temperature not exceeding 100 ° C; supply of koji to the heated material; fermentation of the mixture; then pulverizing the mixture; and feeding the resulting powdered mixture to an oil mixture comprising one obtained from sesame, oil heated at a temperature not exceeding 100 ° C, and an oil obtained from crude sesame, wherein a ratio between the oil mixture and a total amount of the powder mixture and the oil mixture is 60-95% by weight.
Som utgångsmaterial, vilket rikligt innehåller anti- oxidanterna, förutom risgroddarna, vetegroddarna och soja- bönorna, kan man räkna upp växtarter, som beskrivs i den japanska, utlagda, ej granskade patentansökningen,nr 63-79834, dvs korn, adzukiböna, majs, hatomugi (pärlkorn), ärtor och liknande. Enligt studien av föreliggande upp- finnare är risgroddarna, vetegroddarna och sojabönorna de mest föredragna utgàngsmaterialen.As a starting material, which contains abundant antioxidants, in addition to rice sprouts, wheat sprouts and soybeans, one can list plant species described in Japanese Laid-Open, Unexamined Patent Application No. 63-79834, i.e. barley, adzuki bean, corn, hatomugi (pearl barley), peas and the like. According to the study of the present inventors, rice sprouts, wheat sprouts and soybeans are the most preferred starting materials.
Näst efter risgroddar, vetegroddar och sojabönor kan man räkna upp riskli, hatomugi (pärlkorn) och vete. Därför kan, som ett utgångsmaterial, minst en av riskli, hatomugi (pärlkorn) och vete inbegripas tillsammans med risgroddar I vilket fall som helst är förhål- landet mellan groddarna (risgroddar och/eller vetegroddar) och/eller vetegroddar. i sädesutgångsmaterialet företrädesvis åtminstone mer än eller lika med l vikt%.Next to rice sprouts, wheat sprouts and soybeans, you can list rice bran, hatomugi (pearl barley) and wheat. Therefore, as a starting material, at least one of rice bran, hatomugi (pearl barley) and wheat may be included together with rice sprouts. In any case, the relationship between the sprouts (rice sprouts and / or wheat sprouts) and / or wheat sprouts. in the seed starting material, preferably at least more than or equal to 1% by weight.
Antioxidanterna i sädesutgångsmaterialet, som be- skrivits ovan, bildar en komplicerad makromolekylpolymer tillsammans med andra ämnen och har därför ingen aktivitet som sådan. Således är det nödvändigt att man skär av mak- romolekylbindningarna genom mild värmning eller liknande för att frigöra antioxidanterna med låg molekylvikt. Om värmningstemperaturen är för hög deaktiveras emellertid antioxidanterna med låg molekylvikt, således är det nöd- vändigt att man väljer en värmebetingelse med åtanke på detta faktum.The antioxidants in the seed starting material, as described above, form a complex macromolecular polymer together with other substances and therefore have no activity as such. Thus, it is necessary to cut off the macromolecular bonds by gentle heating or the like to release the low molecular weight antioxidants. However, if the heating temperature is too high, the low molecular weight antioxidants are deactivated, so it is necessary to choose a heating condition with this fact in mind.
För att tillgodose sådana betingelser, är det nöd- vändigt att man värmer sädesutgångsmaterialet vid en tem- 10 15 20 25 30 35 512781 5 peratur, som inte överskrider 100°C, sakta och under till- räckligt lång tid. ett kärl gjort av keramik, I detalj sätts sädesutgångsmaterialet i såsom lera eller liknande, som fö- reträdesvis med våglängder av 4-14 um, och värmning utförs utstrålar infraröda strålar i det làngvågiga området, under långsam omröring och bibehållande av temperaturen vid ca 90-96°C.In order to satisfy such conditions, it is necessary to heat the semen starting material at a temperature not exceeding 100 ° C, slowly and for a sufficiently long time. a vessel made of ceramic. In detail, the seed starting material is inserted as clay or the like, which is preferably with wavelengths of 4-14 μm, and heating is performed emitting infrared rays in the long-wave region, with slow stirring and maintaining the temperature at about 90- 96 ° C.
Värmningstiden varierar beroende på sädesarterna, så- ledes kan den inte godtyckligt definieras. Den är emeller- tid företrädesvis ca 3O min-3 h. För övrigt begränsas värm- ningsförfarandet inte till den ovannämnda metoden, förut- satt att antioxidanterna i sädesutgångsmaterialet frigörs tillräckligt som làgmolekylära ämnen, medan deaktivering därav förhindras.The heating time varies depending on the cereals, so it can not be arbitrarily defined. However, it is preferably about 30 minutes to 3 hours. Otherwise, the heating process is not limited to the above-mentioned method, provided that the antioxidants in the semen starting material are released sufficiently as low molecular weight substances, while deactivation thereof is prevented.
Efter värmebehandlingen, som beskrivits ovan, sätts koji (Aspergillus orizae) till utgångsmaterialet för att fermentera detta. Fermenteringsbetingelsen är företrädes- vis 20-36°C under 2-6 dagar. När fermentering utförs med användning av en fermentor är ca 2-3 h tillräckligt. Denna fermentering utförs för att ytterligare gynna frigörning och omvandling av antioxidanterna i sädesutgångsmaterialet till ämnen med låg molekylvikt, och genom detta fermente- ringssteg höjs antioxidanternas aktivitet anmärkningsvärt jämfört med ett utgångsmaterial, som endast utsatts för värmebehandling.After the heat treatment, as described above, koji (Aspergillus orizae) is added to the starting material to ferment it. The fermentation condition is preferably 20-36 ° C for 2-6 days. When fermentation is performed using a fermenter, about 2-3 hours is sufficient. This fermentation is carried out to further promote the release and conversion of the antioxidants in the seed starting material into low molecular weight substances, and through this fermentation step the activity of the antioxidants is remarkably increased compared to a starting material which has only been subjected to heat treatment.
Härefter mals det fermenterade materialet till ett fint pulver. Målning kan utföras med användning av en kom- mersiellt tillgänglig kvarn. Vissa typer av kvarnar gene- rerar emellertid höga temperaturer under användning, var- vid antioxidanterna deaktiveras. Därför föredrar man att använda de kvarnar, som inte genererar höga temperaturer under användning. En stenkvarn kan t ex användas.The fermented material is then ground to a fine powder. Painting can be performed using a commercially available grinder. However, some types of grinders generate high temperatures during use, which deactivate the antioxidants. Therefore, it is preferred to use those mills which do not generate high temperatures during use. A stone mill can be used, for example.
Därefter framställs oljan genom blandning av en olja, som erhålls från värmd sesam (betecknas härefter som se- sampastaolja) med en olja, som erhålls från rå sesam, i ett lämpligt förhållande, och det ovannämnda fina pulvret sätts till oljeblandningen. Sesampastaoljan är en olja, 10 15 20 25 30 35 512781 6 som erhållits genom malning och presning av rå sesam, som värmts sakta vid en temperatur, som inte överskred lOO°C, under en tillräckligt lång tid, varvid det fina, fasta innehållet, förblir som det är, så att utseendet utgör ett pastatill- som bildats genom målning av sesam, emellertid stånd. Denna sesampastaolja innehåller rikliga mängder av antioxidanterna med låg molekylvikt, och genom användning av sesampastaoljan är det möjligt att erhålla oljeprepa- ratet med en hög aktivitet hos antioxidanten.Thereafter, the oil is prepared by mixing an oil obtained from heated sesame (hereinafter referred to as sesame paste oil) with an oil obtained from crude sesame, in a suitable ratio, and the above-mentioned fine powder is added to the oil mixture. The sesame paste oil is an oil obtained by grinding and pressing raw sesame, which is slowly heated at a temperature not exceeding 100 ° C, for a sufficiently long time, the fine, solid content, remains as it is, so that the appearance constitutes a paste- formed by painting sesame, however, stand. This sesame paste oil contains abundant amounts of the low molecular weight antioxidants, and by using the sesame paste oil it is possible to obtain the oil preparation with a high activity of the antioxidant.
Denna sesampastaolja har emellertid en hög viskosi- tet, och storleken hos en droppe är också stor, således har preparatet i vilket endast sesampastaoljan tillförts det ovan beskrivna fina pulvret, en dålig penetreringsmöj- lighet in på insidan av celler i en sjuk del. När sesamol- jan, som erhàllits från rå sesam, sätts till sesampastaol- jan är emellertid droppstorleken liten och penetrerings- möjligheten in på insidan av cellerna i en sjuk del för- bättras.However, this sesame paste oil has a high viscosity, and the size of a drop is also large, thus the preparation in which only the sesame paste oil was added to the fine powder described above has a poor penetration possibility into the inside of cells in a diseased part. However, when the sesame oil obtained from raw sesame is added to the sesame paste oil, the droplet size is small and the possibility of penetration into the inside of the cells in a diseased part is improved.
Oljan, som samlas upp från rå sesam, är en olja, som erhålls genom att rå sesam mals som det är och pressas, varefter det fasta innehållet tas bort och oljan är kom- mersiellt tillgänglig som en vanlig sesamolja. Eftersom blandningsförhållandet mellan sesampastaoljan och den van- liga sesamoljan också skiljer sig åt beroende på mängden som skall tillsättas, kan inte för- hållandet definieras godtyckligt. Företrädesvis är det 1-3 av det fina pulvret, viktdelar av den vanliga sesamoljan per l viktdel av se- sampastaoljan.The oil, which is collected from crude sesame, is an oil obtained by grinding raw sesame as it is and pressing, after which the solid content is removed and the oil is commercially available as a regular sesame oil. Since the mixing ratio between the sesame paste oil and the ordinary sesame oil also differs depending on the amount to be added, the ratio cannot be defined arbitrarily. Preferably it is 1-3 of the fine powder, parts by weight of the ordinary sesame oil per 1 part by weight of the sesame paste oil.
Förhållandet mellan oljeblandningen och det fina pulvret, som sätts därtill, är sådant att den blandade oljan utgör 60-95 vikt% av den totala mängden av båda två.The ratio of the oil mixture to the fine powder added thereto is such that the mixed oil constitutes 60-95% by weight of the total amount of both.
Om oljeblandningen är mindre än 60 vikt%, är möjligheten för oljepreparatet att passera genom cellmembranet dålig.If the oil mixture is less than 60% by weight, the ability of the oil preparation to pass through the cell membrane is poor.
Om å andra sidan oljeblandningen överskrider 95 vikt%, är koncentrationen av antioxidanterna, låg, reaktivt syre och lipidperoxid, också minskar. som effektiva kompo- nenter, varvid effekten, att dämpa framställningen av 10 15 20 25 30 35 512781 7 Oljepreparatet enligt föreliggande uppfinning, vilket tas oralt, kan framställas genom att det fina pulvret sätts till oljeblandningen genom inneslutning i en gela- tinkapsel eller liknande så snart oljeblandningen fram- ställts. Materialblandningen kan emellertid få mogna före- trädesvis vid 20-35°C under ca 3-30 dagar, ännu hellre vid 28-30°C under ca l vecka före inkapsling.On the other hand, if the oil mixture exceeds 95% by weight, the concentration of the antioxidants, low, reactive oxygen and lipid peroxide, also decreases. as effective components, the effect of dampening the preparation of the oil preparation of the present invention, which is taken orally, can be prepared by adding the fine powder to the oil mixture by enclosing it in a gelatin capsule or the like. as soon as the oil mixture is prepared. However, the material mixture may mature preferably at 20-35 ° C for about 3-30 days, even more preferably at 28-30 ° C for about 1 week before encapsulation.
Genom att man tillämpar mogningsbehandlingen fortgår frigörningen och omvandlingen av antioxidanterna till äm- nen med låg molekylvikt vidare med hjälp av koji, som kvarstår i det fina pulvret, och antioxidanterna blandar sig väl med oljeblandningen, varvid de reaktiva komponen- ternas aktivitet och den osmotiska förmågan in på,insidan av cellerna ytterligare förbättras.By applying the maturation treatment, the release and conversion of the antioxidants to low molecular weight substances proceeds by means of koji, which remain in the fine powder, and the antioxidants mix well with the oil mixture, whereby the activity of the reactive components and the osmotic ability in, the inside of the cells is further improved.
Oljepreparatet enligt föreliggande uppfinning kan också omfatta ett sädesutgångsmaterial, som omfattar ris- groddar eller vetegroddar och sojabönor, och eventuellt minst en bland riskli, hatomugi (pärlkorn) eller vete, som omvandlas till ett fint pulver som det är utan värmning och fermentering, och sätts till oljeblandningen tillsam- mans med det värmda och fermenterade fina pulvret, som beskrivits ovan.The oil composition of the present invention may also comprise a seed starting material comprising rice sprouts or wheat sprouts and soybeans, and optionally at least one of rice bran, hatomugi (pearl barley) or wheat, which is converted into a fine powder as it is without heating and fermentation, and added to the oil mixture together with the heated and fermented fine powder, as described above.
I det fina pulvret av sädesutgångsmaterialet, som inte värms och fermenteras, frigörs och omvandlas inte an- tioxidanterna som effektiva komponenter till ämnen med låg mo1ekylvikt¿ När det sätts till oljeblandningen tillsam- mans med det värmda och fermenterade fina pulvret, fortgår emellertid gradvis antioxidanternas frigöring och omvand- ling till ämnen med låg molekylvikt även efter inkapsling fina på grund av koji, som kvarstår i det fermenterade, pulvret, således finns den fördel att effekten av under- tryckning av framställningen av reaktivt syre och lipid- peroxid bibehålls under en lång period.In the fine powder of the seed starting material, which is not heated and fermented, the antioxidants are not released and converted as effective components into low molecular weight substances¿ When added to the oil mixture together with the heated and fermented fine powder, however, the release of the antioxidants gradually proceeds. and conversion to low molecular weight substances even after encapsulation fine due to koji remaining in the fermented powder, thus there is the advantage that the effect of suppressing the production of reactive oxygen and lipid peroxide is maintained for a long period .
I motsats därtill bryts antioxidanterna, som en ef- fektiv komponent, ner i oljepreparatet, i vilket endast värmt och fermenterat fint pulver används, på grund av enzymreaktioner och liknande, vilka kontinuerligt fortgår 10 15 20 25 30 35 512781 8 även efter inkapsling. Sàledes är den effektiva perioden kort jämfört med ett preparat i vilket det icke behandla- de, fina pulvret tillförts.In contrast, the antioxidants, as an effective component, are broken down in the oil preparation, in which only hot and fermented fine powder is used, due to enzyme reactions and the like, which continue continuously even after encapsulation. Thus, the effective period is short compared to a preparation in which the untreated fine powder has been added.
I de fall där tillsatsmängden av det icke behandlade, fina pulvret är för stor minskar emellertid aktiviteten hos den effektiva komponenten. Således föredrar man att det icke behandlade, ca 0,5-l viktdel baserat på en viktdel av det värmda och fina pulvret föreligger i en mängd av fermenterade, fina pulvret. För övrigt är även i detta fall, där tvâ typer av fina pulver inbegripes, oljebland- ningen 60-95 vikt% av den totala mängden.However, in cases where the amount of additive of the untreated fine powder is too large, the activity of the effective component decreases. Thus, it is preferred that the untreated, about 0.5-l weight part based on a part by weight of the heated and fine powder be present in an amount of fermented, fine powder. Incidentally, even in this case, where two types of fine powders are included, the oil mixture is 60-95% by weight of the total amount.
I det således erhållna oljepreparatet enligt förelig- gande uppfinning är bàde antioxidanternas aktivitet och den osmotiska kraften in pà insidan av cellen hög. Vilket också klargjorts fràn resultat av kliniska försök, som be- skrivs härefter, uppvisar preparatet anmärkningsvärd ef- fekt mot olika inflammationer och inrotade sjukdomar för vilka de terapeutiska effekterna har varit otillräckliga med hjälp av konventionella, antiinflammatoriska medel.In the oil preparation thus obtained according to the present invention, both the activity of the antioxidants and the osmotic force inside the cell are high. As has also been clarified from the results of clinical trials, which are described below, the preparation has a remarkable effect against various inflammations and ingrained diseases for which the therapeutic effects have been insufficient by conventional, anti-inflammatory agents.
Oljepreparatet enligt föreliggande uppfinning kan in- kapslas med gelatin eller liknande och tas oralt som ett läkemedel. fräknar och liknande eller rynkor och liknande, I fall av onormal pigmentering, såsom dermatit, kloasma, kan oljepreparatet appliceras direkt pà den angripna de- len. Förutom pà dermatit och liknande, kan oljepreparatet enligt föreliggande uppfinning också appliceras pà vuxen- sjukdomar och inrotade sjukdomar, sàsom kronisk ledreuma- tromboflebit, framàtskridande systemisk sklerem, svàrbehandlade hudsàr Preparatet enligt föreliggande uppfinning tism, Buergers sjukdom, Raynauds sjukdom, och liknande. har även effekter vid behandling och förhindrande av andra föroreningsorsakade sjukdomar, brännskador, yttre sàr, trötthet, bakrus, Dessutom har oljepreparatet enligt föreliggande upp- förstoppning och liknande. finning inga bieffekter, eftersom man endast använder säd, koji och sesam som utgàngsmaterial, således kan preparatet tas oralt som hälsokost för bibehållande och förhöjning av 10 15 20 30 35 512781 9 hälsan. Det är överflödigt att säga att man kan tillsätta hjälpmediciner eller komponenter, som är användbara för hälsan, såsom olika vitaminer, mineraler och liknande, och smakämnen, smakjusteringsmedel, färgmedel och liknande vid framställning av preparatet.The oil composition of the present invention may be encapsulated with gelatin or the like and taken orally as a medicament. freckles and the like or wrinkles and the like. In case of abnormal pigmentation, such as dermatitis, chloasma, the oil preparation can be applied directly to the affected part. In addition to dermatitis and the like, the oil composition of the present invention can also be applied to adult diseases and ingrained diseases, such as chronic articular rheumatoid thrombophlebitis, progressive systemic sclerosis, difficult-to-treat skin ulcers. also has effects in the treatment and prevention of other pollutant-causing diseases, burns, external wounds, fatigue, hangovers. In addition, the oil preparation according to the present has constipation and the like. no side effects, since only grain, koji and sesame are used as starting materials, thus the preparation can be taken orally as a health food for the maintenance and enhancement of health. Needless to say, one can add auxiliary drugs or components which are useful for health, such as various vitamins, minerals and the like, and flavors, taste adjusting agents, coloring agents and the like in the preparation of the preparation.
Utföringsform Vardera en del av risgroddar, sojabönor, riskli, hatomugi (pärlkorn) och vete laddades i ett kärl gjort av lera, som utstrålade infraröd strålning i det làngvàgiga området av 4-14 pm, och värmdes vid 90-96°C under 3 h un- der långsam omröring för att inte bränna vid. Därefter tillsattes koji i en mängd av 3% av den totala mängden för fermentering vid 36-40°C under 72 h. Sedan omvandlades det fermenterade materialet till fint pulver med användning av en stenkvarn. Dessutom maldes de ovannämnda fem sorterna av sädesutgångsmaterial, som inte värmdes och fermentera- des, med en stenkvarn för att erhålla fint pulver i samma mängd. Å andra sidan värmdes sesam på samma sätt som de identifierade materialen ovan, och efter malning med hjälp av en stenkvarn pressades det för att erhålla en sesampas- taolja.Embodiment Each portion of rice sprouts, soybeans, rice bran, hatomugi (pearl barley) and wheat was loaded into a vessel made of clay, which radiated infrared radiation in the long-range range of 4-14 microns, and heated at 90-96 ° C for 3 hours. while stirring slowly so as not to burn. Then the koji was added in an amount of 3% of the total amount for fermentation at 36-40 ° C for 72 hours. Then the fermented material was converted into a fine powder using a stone mill. In addition, the above-mentioned five varieties of seed starting material, which were not heated and fermented, were ground with a stone mill to obtain fine powder in the same amount. On the other hand, sesame was heated in the same manner as the materials identified above, and after grinding with a stone grinder, it was pressed to obtain a sesame paste oil.
Därefter blandades 28,1 viktdelar sesampastaolja med 48,9 viktdelar av en kommersiellt tillgänglig sesamolja; till vilken blandning sattes ll,5 viktdelar av det värmda och fermenterade, icke behandlade, en omrördes tills den var homogen. Den erhållna blandning- fina pulvret och 11,5 viktdelar av det fina pulvret; och den erhållna blandning- en fick mogna vid 28°C under en vecka och inkapslades se- dan i gelatin för att erhålla ett oljepreparat.Then, 28.1 parts by weight of sesame paste oil was mixed with 48.9 parts by weight of a commercially available sesame oil; to which mixture was added 11.5 parts by weight of the heated and fermented, untreated, one was stirred until homogeneous. The resulting fine powder and 11.5 parts by weight of the fine powder; and the resulting mixture was allowed to mature at 28 ° C for one week and then encapsulated in gelatin to obtain an oil preparation.
Föreliggande uppfinnings effekt [I] "In vitro“-försök (1) För ett "in vitro"-försök med avseende på möjlig- heten att komma fram och penetrera till oljiga ställen, sattes oljepreparatet enligt utföringsformen till ett TBA(tiobarbityrsyra)-reaktionssystem, i vilket en oljig, omättad fettsyra (decosahexansyra) bringades att reagera med reaktivt syre, vilket genererades med hjälp av ultra- 10 15 20 25 30 35 512781 10 violetta stràlar och vilket gav lipidperoxid, och under- tryckningsgraden av framställningen av lipidperoxid mättes.Effect of the present invention [I] "In vitro" test (1) For an "in vitro" test with respect to the ability to reach and penetrate oily sites, the oil preparation according to the embodiment was added to a TBA (thiobarbituric acid) reaction system. , in which an oily, unsaturated fatty acid (decosahexanoic acid) was reacted with reactive oxygen, which was generated by means of ultraviolet rays and which gave lipid peroxide, and the degree of suppression of the production of lipid peroxide was measured.
Till 0,l cm3 decosahexansyra, som spätts 100 ggr, sattes 1,8 mg/ml av testprovet av oljepreparatet enligt föreliggande uppfinning, och den framställda lipidperoxiden I TBA-reaktionen blandades 0,2 2 ml 0,1 N HCl och 0,3 ml fos- l,8 mg/ml av testprovet sattes till bland- mättes genom TBA-reaktionen. ml 7% natriumdodecylsulfat, forvolframsyra; ningen; 1 ml av ett reagens, i vilket 0,67% TBA blandats med ättiksyra vid 1:1, tillsattes; med excitation vid 515 nm och emission vid 553 nm med an- och mätningen utfördes vändning av en fluorescensspektrofotometer.To 0.1 cm 3 of decosahexanoic acid, which is diluted 100 times, was added 1.8 mg / ml of the test sample of the oil preparation of the present invention, and the prepared lipid peroxide in the TBA reaction was mixed 0.2 2 ml of 0.1 N HCl and 0.3 ml of phos- 1.8 mg / ml of the test sample was added to mixed by the TBA reaction. ml 7% sodium dodecyl sulphate, tungstic acid; ningen; 1 ml of a reagent in which 0.67% TBA was mixed with acetic acid at 1: 1 was added; with excitation at 515 nm and emission at 553 nm with the measurement and measurement, reversal of a fluorescence spectrophotometer was performed.
Som jämförelseexempel, användes det botaniska närings- ämnet i den japanska patentskriften nr 1 366 268 (jämförel- seexempel l) och antioxidantkompositionen, som beskrivs i den japanska, utlagda, ej granskade patentansökan nr 63-79834, (jämförelseexempel 2), varvid mätningarna utför- des pà samma sätt. Resultaten visas i tabell l.As a comparative example, the botanical nutrient of Japanese Patent Specification No. 1,366,268 (Comparative Example 1) and the antioxidant composition described in Japanese Laid-Open, Unexamined Patent Application No. 63-79834 (Comparative Example 2) were used, the measurements being performed - des in the same way. The results are shown in Table 1.
TABELL 1 Medelvärde Testprov (6 min värde) Kontroll 461 i 62 (UV+) Oljepreparat enligt föreliggande 121 1 13 *** uppfinning (1,8 mg/ml) Jämförelseexempel l 271 1 34 ** (1,8 Ing/ml) Jämförelseexempel 2 358 + 45 * (1,8 mg/ml) UV+: ultraviolett strålning ***: 0,01 < P < 0,05 (jämförelse med kontroll) **: P < 0,01 (jämförelse med kontroll) *: P < 0,000l (jämförelse med kontroll) 10 15 20 25 30 35 512781 ll Testresultat Även om vilket som helst av testproven markant under- tryckte genereringen av lipidperoxid (TBA-reaktiva ämnen) frán den omättade fettsyran (docosahexansyra) med hjälp av strålning av ultravioletta stràlar (102), undertryckte i synnerhet oljepreparatet enligt föreliggande uppfinning. anmärkningsvärt denna generering (P < 0,000l). Resultatet stöder det faktum att oljepreparatet enligt föreliggande uppfinning har en högre aktivitet hos antioxidanten och en högre penetreringsmöjlighet in pà insidan av cellen, i vilken en sjukdom förekommer, jämfört med konventionella preparat (jämförelseexempel 1 och 2). (2) En (3,4-3H2]-antioxiaant framställdes, varvid antioxidanten med làg molekylvikt, som förelàg i oljepre- paratet enligt föreliggande uppfinning, märktes med en isotop (3H); teströr; och antalet (cpm) [3H2], som bundit till cell- preparatet sattes till en human vävnad i ett membranen mättes med hjälp av en scintillationsräknare; varvid möjligheten att komma fram vid cellmembranet under- söktes (märkt, titrerad tymidin var 2 Ci/mM).TABLE 1 Mean Test sample (6 min value) Control 461 in 62 (UV +) Oil preparations according to the present 121 1 13 *** invention (1.8 mg / ml) Comparative Example l 271 1 34 ** (1.8 Ing / ml) Comparative Example 2 358 + 45 * (1.8 mg / ml) UV +: ultraviolet radiation ***: 0.01 <P <0.05 (comparison with control) **: P <0.01 (comparison with control) *: P <0.000l (comparison with control) 10 15 20 25 30 35 512781 ll Test results Although any of the test samples markedly suppressed the generation of lipid peroxide (TBA-reactive substances) from the unsaturated fatty acid (docosahexaenoic acid) by radiation of ultraviolet rays (102), in particular, suppressed the oil preparation of the present invention. remarkable this generation (P <0.000l). The result supports the fact that the oil preparation according to the present invention has a higher activity of the antioxidant and a higher penetration possibility inside the cell in which a disease occurs, compared to conventional preparations (Comparative Examples 1 and 2). (2) A (3,4-3H2] -antioxane was prepared, the low molecular weight antioxidant present in the oil composition of the present invention being labeled with an isotope (3H); test tube; and the number (cpm) [3H2], bound to the cell preparation was added to a human tissue in a membrane was measured using a scintillation counter, examining the possibility of reaching the cell membrane (labeled, titrated thymidine was 2 Ci / mM).
Samma försök utfördes också för jämförelseexemplen 1 och 2. Resultaten visas i tabell 2. Som framgàr av tabell 2, hade oljepreparatet enligt föreliggande uppfinning den högsta affiniteten pà cellmembranet jämfört med jämfö- relseexemplen 1 och 2.The same experiments were also performed for Comparative Examples 1 and 2. The results are shown in Table 2. As shown in Table 2, the oil preparation of the present invention had the highest affinity on the cell membrane compared to Comparative Examples 1 and 2.
TABELL 2 Testprov cpm som inneslutits Kontroll 15643 cpm / 103 celler Oljepreparat enligt 56372 cpm / 103 celler föreliggande uppfinning (1,8 mg/ml) Jämförelseexempel l 33451 cpm / 103 celler (1,8 mg/ml) Jämförelseexempel 2 30567 cpm / 103 celler (1,8 mg/ml) 10 15 20 25 30 35 512781 12 (3) Oljepreparatet enligt föreliggande uppfinning utsattes för ultraljudsbehandling och sattes till ett sys- tem, som genererade reaktivt syre (neutrofil och xantin- xantinoxidas) så att omvandlingskoncentrationen i den levande kroppen blev 1,6 mg/ml; och tre typer av reaktivt syre (02_, HZOZ och OH~) mättes för att jämföra med fallet med ingen tillsättning (kontroll). Omvandlingskoncentatio- existera i nen i en levande kropp är den mängd, som antas blodet när en ordinärt tagen mängd per dag (9 g i fall av oljepreparatet enligt föreliggande uppfinning) absorberas i en levande kropp.TABLE 2 Test sample cpm contained Control 15643 cpm / 103 cells Oil preparation according to 56372 cpm / 103 cells present invention (1.8 mg / ml) Comparative Example 1 33451 cpm / 103 cells (1.8 mg / ml) Comparative Example 2 30567 cpm / 103 cells (1.8 mg / ml) (3) The oil preparation of the present invention was subjected to ultrasonic treatment and added to a system which generated reactive oxygen (neutrophil and xanthine xanthine oxidase) so that the conversion concentration in the living body became 1.6 mg / ml; and three types of reactive oxygen (O 2, H 2 O 2 and OH 2) were measured to compare with the case of no addition (control). The conversion percentage to exist in a living body is the amount that is assumed in the blood when an ordinary amount taken per day (9 g in the case of the oil preparation of the present invention) is absorbed in a living body.
Mätningsförfarandet för de tre typerna av reaktivt syre är enligt följande. , Med avseende pà 02-, användes metoden i vilken reduk- mättes vid en vàglängd av 550 nm med en spektrofotometer av typen tionsmängden av ferricytokrom C med hjälp av 02 Beckman, och detta omvandlades till mängden 02-.The measurement procedure for the three types of reactive oxygen is as follows. With respect to O 2 -, the method was used in which reduct was measured at a wavelength of 550 nm with a spectrophotometer of the type amount of ferric cytochrome C using O 2 Beckman, and this was converted to the amount O 2 -.
Med avseende pà HZOZ, mättes minskningsgraden av sko- poletinfluorescens med användning av skopoletin och per- oxidas beroende pà det faktum att H2O2 minskar fluorescen- sen, som genereras av skopoletin i närvaro av peroxidas, varvid detta mättes med användning av en fluorescens- spektrofotometer gjord av Hitachi Ltd med excitation vid 370 nm och emission vid 460 nm.With respect to HZOZ, the degree of reduction of scopoletin fluorescence using scopoletin and peroxidase was measured due to the fact that H by Hitachi Ltd with excitation at 370 nm and emission at 460 nm.
Med avsende pà OH' användes metoden i vilken man an- vände en princip att a-keto-metiol-butylsyra (KMB) bringades att reagera med OH- för att generera etengas, varvid etengasen kvantifierades med en gaskromatograf gjord av Hitachi Ltd. och varvid denna kvantifiering omvandlades till OH-. Samma försök utfördes också för jämförelseexempel l och 2. Resultaten visas i tabell 3. 10 15 20 25 30 35 512781 13 TABELL 3 Reaktivt syre Testprov 02_ H2O2 OH.With respect to OH ', the method was used in which a principle was used that α-keto-methiol-butyl acid (KMB) was reacted with OH- to generate ethylene gas, the ethylene gas being quantified with a gas chromatograph made by Hitachi Ltd. and wherein this quantification was converted to OH-. The same experiments were also performed for Comparative Examples 1 and 2. The results are shown in Table 3. TABLE 3 Reactive Oxygen Test Sample O 2 H 2 O 2 OH.
Kontroll 1,532 nmol 485 pmol 854 pmol Oljepreparat enligt fö- 0,589 nmol 161 pmol 283 pmol religgande uppfinning (1,3 mg/ml) Jämförelseexempel 1 1,285 nmol 403 pmol 707 pmol (1,8 Ing/ml) Jämförelseexempel 2 0,231 nmol 538 pmol 108 pmol (1,8 mg/ml) Testresultat Antioxidanteffekten hos oljepreparatet enligt före- liggande uppfinning var något sämre jämfört med den i jäm- förelseexempel 2, men uppvisade emellertid en antioxidant- effekt större än den i jämförelseexempel 1. Som klargjorts från de ovannämnda tabellerna 1 och 2 har emellertid jäm- förelseexempel 2 en mindre halt av oljeämnen, varvid det har sämre möjlighet att komma fram till cellen, i vilken en sjukdom förekommer.Control 1.532 nmol 485 pmol 854 pmol Oil preparation according to the pre-0.589 nmol 161 pmol 283 pmol of the present invention (1.3 mg / ml) Comparative Example 1 1.285 nmol 403 pmol 707 pmol (1.8 Ing / ml) Comparative Example 2 0.231 nmol 538 pmol 108 pmol (1.8 mg / ml) Test results The antioxidant effect of the oil preparation of the present invention was slightly worse than that of Comparative Example 2, but showed an antioxidant effect greater than that of Comparative Example 1. As clarified from the above tables 1 and 2, however, Comparative Example 2 has a lower content of oil substances, whereby it has a poorer possibility of reaching the cell in which a disease occurs.
När således en total bedömning görs är oljepreparatet enligt föreliggande uppfinning, i vilket antioxidanteffek- ten är hög och penetreringsförmàgan, in pà insidan av cellen i en sjuk del, är högst, mycket utmärkt som ett antioxideringsmedel.Thus, when an overall assessment is made, the oil composition of the present invention, in which the antioxidant effect is high and the penetration ability, inside the cell in a diseased part, is highest, very excellent as an antioxidant.
[II] Kliniskt försök Den terapeutiska effekten undersöktes hos 96 patien- ter med autoimmunsjukdom, kollagenos, såsom kronisk led- reumatism, hemastenos, nefrit, hepatocirros, kloasma, fräknar och liknande, vilka hittills motstàtt eller blivit värre med vilket som helst av de nonsteriodala, antiflo- gistiska läkemedlen, steroider och antioxidantkompositio- 10 15 20 25 30 35 512781 nen i jämförelseexempel 2. Resultaten visas i tabell 4.[II] Clinical trial The therapeutic effect was studied in 96 patients with autoimmune disease, collagenosis, such as chronic joint rheumatism, hemastenosis, nephritis, hepatocirrosis, chloasma, freckles and the like, which have hitherto resisted or worsened with any of the nonsteriodic , the antiphlogistic drugs, steroids and antioxidant composition of Comparative Example 2. The results are shown in Table 4.
TABELL 4 Oljepreparat enligt före- liggande upp- Testprov Jämförelse- exempel 1 Jämförelse- exempel 2 finning Sjukdom (1,8 mg/ml) (1,8 mg/ml) (1,8 mg/ml) Kronisk 13/18 (72%) 0/7 (O%) 4/14 (28%) ledreuma- tism Angit 3/5 (60%) 0/3 (O%) 1/4 (25%) Framàtskri- 9/12 (75%) 2/10 (20%) 6/12 (50%) dande syste- misk sklerem Dermato- 6/8 (75%) 2/12 (16%) 6/13 (46%) myosytis Trombo- 2/3 (66%) 0/4 (O%) 1/5 (20%) flebit Buergers 6/8 (75%) O/3 (O%) 3/6 (50%) sjukdom Raynauds 10/12 (83%) 3/8 (37%) 7/12 (58%) sjukdom Crus 8/11 (72%) 4/9 (44%) 11/15 (73%) varikos Svàrbehand- 3/5 (60%) 1/5 (20%) 2/6 (33%) lade hudsàr Kloasma, 11/14 (78%) 4/12 (33%) 17/25 (68%) fräknar värdena i tabellen visar andelen patienter med positivt resultat i vart och ett av fallen.TABLE 4 Oil preparations according to the present test Test Comparative Example 1 Comparative Example 2 Finding Disease (1.8 mg / ml) (1.8 mg / ml) (1.8 mg / ml) Chronic 13/18 (72 %) 0/7 (O%) 4/14 (28%) joint rheumatism Indicated 3/5 (60%) 0/3 (O%) 1/4 (25%) Forward- 9/12 (75%) 2/10 (20%) 6/12 (50%) dande systemic sclera Dermato- 6/8 (75%) 2/12 (16%) 6/13 (46%) myosytis Thrombo- 2/3 (66 %) 0/4 (O%) 1/5 (20%) phlebitis Burgers 6/8 (75%) U / 3 (O%) 3/6 (50%) Raynaud's disease 10/12 (83%) 3 / 8 (37%) 7/12 (58%) Disease Crus 8/11 (72%) 4/9 (44%) 11/15 (73%) Varicose Violence Treatment- 3/5 (60%) 1/5 (20 %) 2/6 (33%) added skin ulcer Kloasma, 11/14 (78%) 4/12 (33%) 17/25 (68%) freckles the values in the table show the proportion of patients with positive results in each of the cases .
Claims (7)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4162666A JP2955126B2 (en) | 1992-06-22 | 1992-06-22 | Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
SE9302141D0 SE9302141D0 (en) | 1993-06-21 |
SE9302141L SE9302141L (en) | 1993-12-23 |
SE512781C2 true SE512781C2 (en) | 2000-05-15 |
Family
ID=15758977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9302141A SE512781C2 (en) | 1992-06-22 | 1993-06-21 | Oil preparations with high activity antioxidants, and process for their preparation |
Country Status (20)
Country | Link |
---|---|
JP (1) | JP2955126B2 (en) |
KR (1) | KR0138738B1 (en) |
CN (1) | CN1065433C (en) |
AT (1) | AT406935B (en) |
AU (1) | AU656681B2 (en) |
BE (1) | BE1006911A3 (en) |
CA (1) | CA2098893C (en) |
CH (1) | CH686482A5 (en) |
DE (1) | DE4320526C2 (en) |
DK (1) | DK169714B1 (en) |
ES (1) | ES2049189B1 (en) |
FR (1) | FR2692442B1 (en) |
GB (1) | GB2268185B (en) |
HK (1) | HK1007165A1 (en) |
IS (1) | IS1657B (en) |
IT (1) | IT1266950B1 (en) |
NL (1) | NL193398C (en) |
NO (1) | NO306932B1 (en) |
SE (1) | SE512781C2 (en) |
TW (1) | TW269630B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2946548A (en) * | 1956-09-10 | 1960-07-26 | Lars G V Largelins | Supporting clamp |
GB9509811D0 (en) * | 1995-05-15 | 1995-07-05 | Cerestar Holding Bv | Co-pressing of oilseeds |
DE19715878A1 (en) * | 1997-04-16 | 1998-10-22 | Pharmaberatung Fuer Ernaehrung | Products to aid the treatment of atopic dermatitis |
JPH11269066A (en) * | 1998-03-20 | 1999-10-05 | Kao Corp | Skin-bleaching agent for peroral administration and skin-bleaching food |
AUPP574298A0 (en) * | 1998-09-07 | 1998-10-01 | Jacobs, David Ian | Pharmaceutical preparation |
JP2000159682A (en) * | 1998-09-17 | 2000-06-13 | Kozo Niwa | Method of strengthening antitumor activity of crude drug, composition containing crude drug for strengthening antitumor activity, method of evaluating antitumor effectivity treated by crude drug and method of evaluating antitumor effectivity of crud drug |
JP2000239187A (en) * | 1999-02-22 | 2000-09-05 | Dotto:Kk | Transnasal absorption composition |
JP2001199892A (en) * | 2000-01-17 | 2001-07-24 | Kozo Niwa | Method for enhancing antitumor activity of amygdalin- containing material, composition containing amygdalin- containing material for enhancing antitumor activity, method for evaluating antitumor effectiveness of treatment by amygdalin-containing material, and method for evaluating antitumor effectiveness of amygdalin- contaning material |
JP4621444B2 (en) * | 2004-06-18 | 2011-01-26 | 株式会社ヴァリダックス | Method for producing antitumor substance |
DE102007011985B4 (en) | 2007-03-09 | 2022-10-20 | Markus Greim | Mortar measuring cell for rotation viscometer |
FR2956324A1 (en) * | 2010-01-18 | 2011-08-19 | Valerie Baille | Plant complex, useful to e.g. prepare a composition in pharmaceutical, cosmetic or nutrition, comprises a bamboo polyphenolic extract, a cell preparation of Ginkgo biloba and a rice bran oil preparation |
CN104178334A (en) * | 2013-05-24 | 2014-12-03 | 北京中天金谷粮油工程技术有限公司 | Process for infrared baking of sesame to produce oil |
JP2021031439A (en) * | 2019-08-26 | 2021-03-01 | 雄二 松川 | Method for producing active oxygen scavenger for oral ingestion that suppresses runaway of immune cells and protects against dna and telomere damage |
JP2021031440A (en) * | 2019-08-26 | 2021-03-01 | 雄二 松川 | Antitumor agent set having active oxygen removing agent containing low molecular antioxidizing compound derived from natural product and immunity activator derived from natural product which is used for enhancing macrophages and lymphocytes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6020389B2 (en) * | 1983-06-07 | 1985-05-21 | 工業技術院長 | Separation method of tocopherols |
JPS60110269A (en) * | 1983-11-18 | 1985-06-15 | Kimimoto Wada | Preparation of vegetable nutrient |
JPS6236327A (en) * | 1985-08-08 | 1987-02-17 | Kozo Niwa | Chinese herbal remedy |
JPS6379834A (en) * | 1986-09-25 | 1988-04-09 | Kozo Niwa | Active oxygen suppressive composition |
JPH023495A (en) * | 1988-06-13 | 1990-01-09 | Okuno Seiyaku Kogyo Kk | Antioxidant |
JPH0441436A (en) * | 1990-06-04 | 1992-02-12 | Sodetsukusu Kk | Antioxidant composition |
JPH07119176B2 (en) * | 1990-09-28 | 1995-12-20 | アサヒビール株式会社 | Anti-active oxygen acting composition and anti-active oxygen agent containing the same as an active ingredient, food, cosmetics and pharmaceuticals |
JP3357383B2 (en) * | 1991-08-14 | 2002-12-16 | 昌宏 黒田 | Low molecular weight plant composition |
JP2647774B2 (en) * | 1991-11-28 | 1997-08-27 | 株式会社 エイオーエイ・ジャパン | Plant antioxidant composition |
-
1992
- 1992-06-22 JP JP4162666A patent/JP2955126B2/en not_active Expired - Lifetime
-
1993
- 1993-06-21 DE DE4320526A patent/DE4320526C2/en not_active Expired - Lifetime
- 1993-06-21 GB GB9312763A patent/GB2268185B/en not_active Expired - Lifetime
- 1993-06-21 SE SE9302141A patent/SE512781C2/en unknown
- 1993-06-21 NO NO932282A patent/NO306932B1/en not_active IP Right Cessation
- 1993-06-21 DK DK073293A patent/DK169714B1/en not_active IP Right Cessation
- 1993-06-21 IT IT93TO000448A patent/IT1266950B1/en active IP Right Grant
- 1993-06-21 CH CH186493A patent/CH686482A5/en not_active IP Right Cessation
- 1993-06-21 CA CA002098893A patent/CA2098893C/en not_active Expired - Lifetime
- 1993-06-22 IS IS4038A patent/IS1657B/en unknown
- 1993-06-22 CN CN93109052A patent/CN1065433C/en not_active Expired - Lifetime
- 1993-06-22 AT AT0122893A patent/AT406935B/en not_active IP Right Cessation
- 1993-06-22 BE BE9300641A patent/BE1006911A3/en not_active IP Right Cessation
- 1993-06-22 NL NL9301083A patent/NL193398C/en not_active IP Right Cessation
- 1993-06-22 FR FR9307557A patent/FR2692442B1/en not_active Expired - Lifetime
- 1993-06-22 ES ES09301404A patent/ES2049189B1/en not_active Expired - Fee Related
- 1993-06-22 KR KR1019930011403A patent/KR0138738B1/en not_active IP Right Cessation
- 1993-06-22 TW TW082104986A patent/TW269630B/zh not_active IP Right Cessation
- 1993-06-22 AU AU41432/93A patent/AU656681B2/en not_active Expired
-
1998
- 1998-06-24 HK HK98106356A patent/HK1007165A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3732254C2 (en) | Natural antioxidants and process for their manufacture | |
SE512781C2 (en) | Oil preparations with high activity antioxidants, and process for their preparation | |
JPH09227398A (en) | Antiobese agent | |
JP2001200250A (en) | Antioxidant | |
JP5024978B2 (en) | Antioxidant | |
JP2004238519A (en) | Extract having antioxidant activity and ultraviolet-absorbing activity, external preparation for skin, and food | |
RU2374858C2 (en) | "molodetskoye" oil composition and its production method | |
KR100550165B1 (en) | Manufacturing method of water-soluble propolis | |
KR20180125757A (en) | Method for extracting an effective ingredient of a pawpaw tree having excellent functionality and a composition containing the extract | |
JP2647774B2 (en) | Plant antioxidant composition | |
JP2001181197A (en) | Olive extract | |
KR20120032690A (en) | Cosmetic composition with the immunoprotective effect | |
KR101273518B1 (en) | Natural fermentation hair restorer and the manufacturing method thereof | |
CN107303255B (en) | Sorghum fermentation product having anti-inflammatory, anti-allergic and atopic skin improving effects, its preparation method and cosmetic composition | |
KR20030084274A (en) | Grain flour and the manufacturing process for skin beauty culture | |
JPH09187248A (en) | Antiallergic food | |
JPH09143091A (en) | Composition having active oxygen-scavenging ability | |
JP2005336137A (en) | Method for producing active oxygen-eliminating agent and use of the same | |
JP2002326945A (en) | Prophylactic agent for ultraviolet hazard | |
KR20160058206A (en) | A composition comprising black sticky rice with giant embryo having anti-oxidation activity | |
JP2001288116A (en) | Active oxygen resistant composition and method of producing the same | |
JP2005325034A (en) | Singlet oxygen eliminator | |
KR20210102662A (en) | Food and cosmetics that include the method of manufacturing oil at the end of microbial fermentation, horse oil, and horse oil. | |
CN117959233A (en) | Biological material for resisting blue light damage and preparation method and application thereof | |
JP2000224970A (en) | Active oxygen-depressing composition, medicine for external use, alcoholic drink and production of the same composition |